Anna R Giuliano1, Matthys H Botha, Michele Zeier, Martha E Abrahamsen, Richard H Glashoff, Louvina E van der Laan, Mary Papenfuss, Susan Engelbrecht, Maarten F Schim van der Loeff, Staci L Sudenga, Benji N Torres, Siegfried Kipping, Douglas Taylor. 1. *Center for Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL; †Department of Obstetrics and Gynaecology and Unit for Gynaecological Oncology, Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa; ‡Department of Medicine and Centre for Infectious Diseases, Stellenbosch University, Cape Town, South Africa; §Division of Medical Virology, Stellenbosch University and NHLS Tygerberg, Cape Town, South Africa; ‖Department of Research, Cluster Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands; ¶Department of Internal Medicine, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, Amsterdam, the Netherlands; and #FHI 360, Durham, NC.
Abstract
BACKGROUND: This study sought to assess the feasibility of conducting a phase III HIV prevention trial using a multivalent human papillomavirus (HPV) vaccine (Gardasil; Merck, Whitehouse Station, NJ). METHODS: A total of 479 sexually active women aged 16-24 years in the Western Cape, South Africa, were enrolled in the Efficacy of HPV Vaccine to Reduce HIV Infection (EVRI) Trial. Of these, 402 were HIV negative, nonpregnant, and randomized 1:1 to receive Gardasil or a saline placebo vaccine. Vaccine doses were administered at enrollment, month 2, and month 6, and participants were followed for 1 month after the third dose. Enrollment HIV, HPV, other sexually transmitted infections (STIs), and cervical cytology were evaluated. Rates of accrual, vaccine compliance, and adherence to protocol were monitored. RESULTS: High rates of accrual of eligible females to study (93%) and completion of the 3-dose vaccine series (91%) were noted, with few protocol violations. Ineligibility due to reported HIV positivity was 19%, and another 12% of those enrolled tested HIV positive. STI prevalence was high, with 6.2%, 10.9%, and 32.8% testing positive for syphilis, gonorrhea, and chlamydia, respectively. Cervical prevalence of ≥1 of 37 HPV types was 71%. STI and HPV prevalence was highest among the youngest women (<19 years). CONCLUSIONS:Feasibility (successful accrual, retention, and vaccination) of conducting randomized placebo-controlled trials of HPV vaccines among HIV high-risk women in South Africa was demonstrated. This work demonstrates that phase III HIV prevention trials need to intervene at young ages and screen and treat multiple STIs concurrently to have a measurable impact on HIV acquisition.
RCT Entities:
BACKGROUND: This study sought to assess the feasibility of conducting a phase III HIV prevention trial using a multivalent human papillomavirus (HPV) vaccine (Gardasil; Merck, Whitehouse Station, NJ). METHODS: A total of 479 sexually active women aged 16-24 years in the Western Cape, South Africa, were enrolled in the Efficacy of HPV Vaccine to Reduce HIV Infection (EVRI) Trial. Of these, 402 were HIV negative, nonpregnant, and randomized 1:1 to receive Gardasil or a saline placebo vaccine. Vaccine doses were administered at enrollment, month 2, and month 6, and participants were followed for 1 month after the third dose. Enrollment HIV, HPV, other sexually transmitted infections (STIs), and cervical cytology were evaluated. Rates of accrual, vaccine compliance, and adherence to protocol were monitored. RESULTS: High rates of accrual of eligible females to study (93%) and completion of the 3-dose vaccine series (91%) were noted, with few protocol violations. Ineligibility due to reported HIV positivity was 19%, and another 12% of those enrolled tested HIV positive. STI prevalence was high, with 6.2%, 10.9%, and 32.8% testing positive for syphilis, gonorrhea, and chlamydia, respectively. Cervical prevalence of ≥1 of 37 HPV types was 71%. STI and HPV prevalence was highest among the youngest women (<19 years). CONCLUSIONS: Feasibility (successful accrual, retention, and vaccination) of conducting randomized placebo-controlled trials of HPV vaccines among HIV high-risk women in South Africa was demonstrated. This work demonstrates that phase III HIV prevention trials need to intervene at young ages and screen and treat multiple STIs concurrently to have a measurable impact on HIV acquisition.
Authors: Dorina Onoya; Priscilla Reddy; Sibusiso Sifunda; Delia Lang; Gina M Wingood; Bart van den Borne; Robert A C Ruiter Journal: Womens Health Issues Date: 2012-01-21
Authors: Ali Rowhani-Rahbar; Frances B Alvarez; Janine T Bryan; James P Hughes; Stephen E Hawes; Noel S Weiss; Laura A Koutsky Journal: J Clin Virol Date: 2011-12-30 Impact factor: 3.168
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Karen K Smith-McCune; Stephen Shiboski; Mike Z Chirenje; Tsitsi Magure; Jennifer Tuveson; Yifei Ma; Maria Da Costa; Anna-Barbara Moscicki; Joel M Palefsky; Rudo Makunike-Mutasa; Tsungai Chipato; Ariane van der Straten; George F Sawaya Journal: PLoS One Date: 2010-04-08 Impact factor: 3.240
Authors: Peter V Chin-Hong; Marla Husnik; Ross D Cranston; Grant Colfax; Susan Buchbinder; Maria Da Costa; Teresa Darragh; Dana Jones; Franklyn Judson; Beryl Koblin; Kenneth H Mayer; Joel M Palefsky Journal: AIDS Date: 2009-06-01 Impact factor: 4.177
Authors: Catherine F Houlihan; Natasha L Larke; Deborah Watson-Jones; Karen K Smith-McCune; Stephen Shiboski; Patti E Gravitt; Jennifer S Smith; Louise Kuhn; Chunhui Wang; Richard Hayes Journal: AIDS Date: 2012-11-13 Impact factor: 4.177
Authors: Staci L Sudenga; B Nelson Torres; Matthys H Botha; Michele Zeier; Martha E Abrahamsen; Richard H Glashoff; Susan Engelbrecht; Maarten F Schim Van der Loeff; Louvina E Van der Laan; Siegfried Kipping; Douglas Taylor; Anna R Giuliano Journal: J Infect Date: 2015-10-19 Impact factor: 6.072
Authors: Lynette J Menezes; Ubin Pokharel; Staci L Sudenga; Matthys H Botha; Michele Zeier; Martha E Abrahamsen; Richard H Glashoff; Susan Engelbrecht; Maarten F Schim van der Loeff; Louvina E van der Laan; Siegfried Kipping; Douglas Taylor; Anna R Giuliano Journal: Sex Transm Infect Date: 2017-05-10 Impact factor: 3.519
Authors: Maanda Mudau; Remco P Peters; Lindsey De Vos; Dawie H Olivier; Dvora J Davey; Edwin S Mkwanazi; James A McIntyre; Jeffrey D Klausner; Andrew Medina-Marino Journal: Int J STD AIDS Date: 2017-08-11 Impact factor: 1.359
Authors: Zizipho Z A Mbulawa; Cari van Schalkwyk; Nai-Chung Hu; Tracy L Meiring; Shaun Barnabas; Smritee Dabee; Heather Jaspan; Jean-Mari Kriek; Shameem Z Jaumdally; Etienne Muller; Linda-Gail Bekker; David A Lewis; Janan Dietrich; Glenda Gray; Jo-Ann S Passmore; Anna-Lise Williamson Journal: PLoS One Date: 2018-01-02 Impact factor: 3.240
Authors: Staci L Sudenga; B Nelson Torres; Matthys H Botha; Michele Zeier; Martha E Abrahamsen; Richard H Glashoff; Susan Engelbrecht; Maarten F Schim Van der Loeff; Louvina E Van der Laan; Siegfried Kipping; Douglas Taylor; Anna R Giuliano Journal: Papillomavirus Res Date: 2017-02-16
Authors: Brooke E Howitt; Michael Herfs; Tamiwe Tomoka; Steve Kamiza; Tarik Gheit; Massimo Tommasino; Philippe Delvenne; Christopher P Crum; Danny Milner Journal: J Glob Oncol Date: 2016-08-10
Authors: Lyndsey R Buckner; Angela M Amedee; Hannah L Albritton; Pamela A Kozlowski; Nedra Lacour; Chris L McGowin; Danny J Schust; Alison J Quayle Journal: PLoS One Date: 2016-01-05 Impact factor: 3.240